Cencora(COR) - 2021 Q2 - Earnings Call Presentation

Q2 FY2021 Financial Performance - Revenue remained consistent year-over-year at $49.2 billion, reflecting a 3.7% increase[4] - Gross profit increased by 10.5% to $1.5 billion on a GAAP basis, and by 6.7% to $1.5 billion on an adjusted (non-GAAP) basis[4] - Operating income saw a significant rise of 101.7% to $624 million on a GAAP basis, and a 5.2% increase to $707 million on an adjusted (non-GAAP) basis[4] - Net income attributable to AmerisourceBergen decreased by 54.7% to $435 million on a GAAP basis, but increased by 5.4% to $524 million on an adjusted (non-GAAP) basis[4] - Diluted earnings per share decreased by 54.7% to $2.10 on a GAAP basis, but increased by 5.4% to $2.53 on an adjusted (non-GAAP) basis[4] Segment Performance - Pharmaceutical Distribution Services revenue increased to $47.1 billion from $45.6 billion, driven by strong specialty product sales[5] - Pharmaceutical Distribution Services operating income increased to $589 million from $563 million, primarily due to growth in sales of specialty products[5] - Global Commercialization Services & Animal Health (Other) revenue increased to $2.1 billion from $1.9 billion, with growth across all three operating segments[6] - Global Commercialization Services & Animal Health (Other) operating income increased to $123 million from $108 million, driven by the performance of World Courier and MWI[6] FY2021 Guidance (Adjusted Non-GAAP) - Revenue is expected to grow by a high-single digit percentage[7] - Diluted earnings per share are projected to be in the range of $8.45 to $8.60[7] - Free cash flow is estimated to be approximately $1.5 billion[7]